Edgemond James, who serves as Chief Financial Officer and Treasurer of United Therapeutics Corp (NASDAQ: UTHR), completed a sale of 8,987 shares of the company’s common stock on March 23, 2026, generating proceeds of approximately $5.27 million. The transactions took place at prices between $518.283 and $536.275 per share.
That trading day came as United Therapeutics shares were near their 52-week high of $548.12, following a cumulative gain of roughly 63% over the prior 12 months.
Also on March 23, James exercised stock options to acquire 10,000 shares at an exercise price of $135.42 per share, representing a total outlay of $1,354,199 for those options.
After accounting for the option exercise and the sale, James directly holds 18,876 shares of United Therapeutics common stock.
The reported trades were carried out pursuant to a Rule 10b5-1 trading plan that James entered into on October 31, 2025. According to InvestingPro analysis cited in public filings, United Therapeutics currently appears on the Most Overvalued list when measured against Fair Value calculations.
Separately, United Therapeutics has reported a stream of company-level developments attracting investor attention. The firm published results from its phase 3 TETON-2 study in the New England Journal of Medicine. The trial evaluated nebulized Tyvaso for the treatment of idiopathic pulmonary fibrosis and met its primary endpoint, showing a statistically significant improvement in lung function compared with placebo over a 52-week treatment period.
In addition to the clinical update, United Therapeutics authorized a $2 billion stock repurchase program. The program includes an initial $1.5 billion accelerated share repurchase agreement with Citibank and leaves an additional $500 million available at the company’s discretion.
Analyst coverage has reflected positive sentiment toward the company’s prospects. Cantor Fitzgerald raised its price target on United Therapeutics to $625 and maintained an Overweight rating, citing expectations tied to the company’s TETON-1 trial. TD Cowen reiterated a Buy rating with a $575 price target.
Together, the insider transactions, clinical data publication, buyback authorization and analyst target changes form the current set of public disclosures and market signals surrounding United Therapeutics.